Amphastar Pharmaceuticals Inc [AMPH] stock is trading at $25.5, up 3.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The AMPH shares have gain 4.00% over the last week, with a monthly amount drifted -3.85%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amphastar Pharmaceuticals Inc [NASDAQ: AMPH] stock has seen the most recent analyst activity on August 12, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $36 for it. Previously, JP Morgan downgraded its rating to Neutral on May 12, 2025, and kept the price target unchanged to $30. On February 04, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $36 on the stock. Wells Fargo started tracking the stock assigning an Equal Weight rating and suggested a price target of $55 on November 22, 2024. JP Morgan initiated its recommendation with an Overweight and recommended $60 as its price target on March 05, 2024. BofA Securities started tracking with a Neutral rating for this stock on November 17, 2023, and assigned it a price target of $63.
Amphastar Pharmaceuticals Inc [AMPH] stock has fluctuated between $20.39 and $53.96 over the past year. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Amphastar Pharmaceuticals Inc [NASDAQ: AMPH] shares were valued at $25.5 at the most recent close of the market. An investor can expect a potential return of 25.49% based on the average AMPH price forecast.
Analyzing the AMPH fundamentals
Amphastar Pharmaceuticals Inc [NASDAQ:AMPH] reported sales of 722.68M for the trailing twelve months, which represents a drop of -4.38%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at 0.25%, Pretax Profit Margin comes in at 0.22%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.18 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.63 points at the first support level, and at 23.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.99, and for the 2nd resistance point, it is at 26.47.
Ratios To Look Out For
For context, Amphastar Pharmaceuticals Inc’s Current Ratio is 3.29. On the other hand, the Quick Ratio is 2.21, and the Cash Ratio is 1.06. Considering the valuation of this stock, the price to sales ratio is 1.64, the price to book ratio is 1.57 and price to earnings (TTM) ratio is 9.55.
Transactions by insiders
Recent insider trading involved Petersen Floyd F., Director, that happened on Oct 01 ’25 when 500.0 shares were sold. Director, Petersen Floyd F. completed a deal on Oct 01 ’25 to buy 500.0 shares. Meanwhile, Director Petersen Floyd F. sold 500.0 shares on Sep 02 ’25.
